Wikipedia -WSS

Wikipedia

author：fashion 2025-09-28 21:05:21 - browse：44953

NICOLAS MAETERLINCK/BELGA MAG/AFP via Getty Images

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own.

The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s Covid shot going forward as well as to try to combine the vaccine with Sanofi’s own flu shot. The pact includes a $500 million upfront payment, with up to $700 million more on the table if certain regulatory and launch milestones are reached.

While Novavax’s stock soared during the pandemic as the vaccine race was underway, the company failed to get its shot authorized in the U.S. market until July 2022, long after the makers of mRNA vaccines had reaped billions in sales. Sales have sputtered along since then, and last year, the Maryland-based company warned that that it may not be able to stay in business.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Smaller biotechs seek to piggyback on weight loss drug boom

WSS

STAT Summit: The economic case for universal basic health care

How to ethically and practically extend health care to all

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

How AI can help patients find reliable information about doctors

A controversial new treatment promises to make little people taller

Is there really a nursing shortage in the U.S.?

hotspot

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Roivant's CEO is a star, but biotech's black hole persists

Psychedelics group wrestles with new pharma identity

ADCs take center stage as promising cancer treatments

Trump demands the U.S. pay no more for drugs than other countries … again

How to ethically and practically extend health care to all

FDA approval of Sarepta Duchenne genetic therapy gives me hope

J&J lung cancer data amount to new salvo against AstraZeneca

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Roivant's CEO is a star, but biotech's black hole persists

focus

Florida officials tell state schools to teach AP Psychology 'in its entirety'

Study on Amgen’s bispecific immunotherapy produces positive data

It costs an awful lot of money to give away a kidney

How I helped Pfizer think through the ethics of Viagra

Is there really a nursing shortage in the U.S.?

Medicare slashes safety net hospital payments by nearly $1 billion

explore

focus

explore

focus